Personal care products are used increasingly, resulting in growing concern concerning their potential disruption of normal hormonal functions. Recent results on the bioaccumulation of cosmetic ingredients in wildlife and humans point to the need for an in-depth analysis for endocrine activity, in particular with respect to their influence on the androgen (AR), glucocorticoid (GR), and thyroid hormone receptors (TRs). Furthermore, humans are commonly exposed simultaneously to complex mixtures of endocrine active compounds. We have therefore examined 3 frequently used cosmetic ingredients: 2-methylresorcinol (2MR), butylated hydroxyanisole (BHA) and avobenzone (AVB), for (anti)-androgen-, (anti)-glucocorticoid-, and (anti)-thyroid hormone-like activities. Their binary and ternary mixtures at EC 50 or IC 50 concentrations have also been examined for anti-androgen-, glucocorticoid-, and thyroid hormone-like activities. In the MDA-kb2 reporter cell line, compounds possessed anti-androgen-, glucocorticoid-, and anti-glucocorticoid-like activities (except AVB). A new cell line, GH3.TRE-Luc, was used to evaluate anti-thyroid and thyroid hormone-like activities. The combinations 2MR þ BHA and 2MR þ BHA þ AVB have glucocorticoid-like activity: only 2MR þ AVB has anti-androgen-like activity. On the other hand, binary and ternary mixtures of compounds showed no thyroid hormone-like activity. Thus, in addition to identifying new endocrine disrupting compounds, it is also necessary to determine the effects of their mixtures in order to assess fully their risk to human health.
The European Union Cosmetics Directive (76/768/EEC), consolidated version, 2004, defines "personal care products" (PCPs), or cosmetics, as any substance or preparation intended to be in contact with external parts of the human body: epidermis, hair system, nails, lips and external genital organs, or with the teeth and mucous membranes of the oral cavity for the purpose of cleaning them, perfuming them, changing their appearance and/or correcting body odors and/or protecting them or keeping them in good condition. These products include soap, shower gels, shampoos, shaving cream, toothpaste, make-up, skin creams, and perfume. PCPs have become essential products for widespread use (Caliman and Gavrilescu, 2009; Daughton and Ternes, 1999) . These products have therefore to be assessed and adequately managed to avoid harmful effects.
The ingredients in cosmetic products can be persistent and bioactive, and exhibit accumulation potential as well as cause disruption of endocrine activities. Some of these ingredients are showing signs of being of environmental concern (Dhanirama et al., 2012) . Despite the fact that some are in contact use as active ingredients or preservatives in PCPs, their effects on their subject and their environmental fate have met with little scientific attention (Dhanirama et al., 2012) . The hormone-like activity of some of these chemicals was discovered long after they were released into the environment (Sonnenschein and Soto, 1998) . Three compounds have therefore been chosen and tested for possible hormone-like activity, both singly and mixed employing 3 in vitro assays. The compounds were selected for their different uses in cosmetic formulations: 2-methylresorcinol (2MR), an oxidative hair dye, butylated hydroxyanisole (BHA), an antioxidant, and avobenzone (AVB), a UV blocker (Figure 1 ).
Chemicals were selected on the basis of their daily use, high level of production, potential for bioaccumulation and for the lack of adequate reports on possible endocrine disruption. 2MR is the most frequently used oxidative hair dye substance in cosmetic formulations and used at concentrations between 1 and 5% (Table 1) . Although one report stresses that it is safe for use in present practices of use and concentration in a second one it is categorized as a potent skin sensitizer at 2% concentration (College report, 1986; Yazar et al., 2009) . BHA is a widely used food antioxidant but is also used in food packaging, cosmetics, pharmaceuticals, and rubber and petroleum products (Dhanirama et al., 2012; Jos et al., 2005; Smeds and Saukko, 2003; Sonnenschein and Soto, 1998) . Long-term exposure to BHA may be of concern because of its ability to bioaccumulate (Jos et al., 2005) . AVB is used as a photostabilizer, as a treatment for photodermatoses and as a UV filter in many cosmetic and sunscreen products (Felix et al., 1998) . Furthermore, the U.S. Food and Drug Administration has classified AVB as an indirect food additive (Okereke et al., 1995) . Because of its topical application, its percutaneous absorption and bioaccumulation in the body is of great concern for human health (Felix et al., 1998; Schlumpf et al., 2001) .
Compounds were tested at their EC 50 or IC 50 concentrations as mixtures, since humans are exposed to potential hormonelike disruptors simultaneously . Mixtures of hormone-like compounds that mirror the real picture of human exposure are studied. Exposure of humans to selected compounds can be direct, following the use of different cosmetic products, or through the environment. Concentrations of 2MR found in cigarettes range from 0.65 to 5.7 lg/cig. (Moldoveanu and Kiser, 2007) . Smeds and Saukko (2003) also reported concentrations of BHA in adipose tissue (Table 1 ). Compounds present in rivers, lakes and various water samples can also be sources for human exposure. Detailed concentrations are listed in Table 1 .
The main objective of this work was to determine the endocrine disrupting activity of 3 widely used cosmetic ingredients and their mixtures on 3 different nuclear receptors, androgen (AR), glucocorticoid (GR), and thyroid hormone receptor (TR). We decided to test endocrine disrupting activity of mixtures at EC 50 or IC 50 concentrations, which we determined before for each compounds alone. To our knowledge, in vitro studies for hormone-like activities of 2MR, BHA, and AVB have been rare. Furthermore, mixtures of tested compounds have not been analyzed before for endocrine disrupting activity. This study also adds to the very limited knowledge on the possible endocrine disruption of daily used cosmetic formulations. Furthermore, it also stresses both the effects of mixtures and the necessity of including them in risk assessment. 2MR (98% pure, CAS no. 608-25-3 and butylated hydroxyanisol (BHA, 96% pure, CAS no. 25013-16-5) were obtained from Acros Organics (Geel, Belgium). 1-(4-tert-butylphenyl)-3-(-4-methoxyphenyl)-1,3-propanedione (AVB, >98% pure, CAS no. 70356-09-1) was from TCI, Belgium. Bisphenol A (BPA, >99% pure, CAS no. 80-05-7), hydrocortisone (HC, ! 98% pure, CAS no. 50-23-7), dihydrotestosterone (DHT, ! 97.5% pure, CAS no. 521-18-6), flutamide (FLUT, ! 99% pure, CAS no. 13311-84-7), mifepristone (RU-486, ! 98% pure, CAS no. 84371-65-3) and 3,3 0 ,5-triiodo-L-thyronine (T 3 , ! 95% pure, CAS no. 6893-02-3) were from SigmaAldrich, Germany. All compounds were dissolved in dimethyl sulfoxide (DMSO, 99.9% pure, Sigma-Aldrich, Germany). Luciferase Reporter Gene Assay AR and GR reporter gene assays using MDA-kb2 cell line. MDA-kb2 cell line cells (ATCC, USA), stably transformed with murine mammalian tumor virus (MMTV)-luciferase neo reporter construct, were cultured at 37 C without CO 2 in Leibovitz's L-15 medium with 10% fetal bovine serum (Gibco), 100 U/ml penicillin (Sigma), 100 mg/ml streptomycin (Sigma). Cells express both functional endogenous AR and GR, which can both activate MMTV luciferase reporter (Wilson et al., 2002) . For experiments, the cells were seeded at 1 Â 10 5 cells/ml (100 ll/well) in 96-well luminometer plates. After 24 h incubation, the medium was removed and replaced with dosing medium. The MDA-kb2 cells were exposed to FLUT, DHT, HC, vehicle-control, and the tested compounds for another 24 h. The compounds were tested at a concentration range shown not to be cytotoxic. After rinsing 3 times with phosphate-buffered saline (pH 7.4), the cells were treated with 5Â cell lysis reagent (Promega, Madison, Wisconsin, USA). Murray et al., 2010) was converted to fold induction above the corresponding vehicle control value (0.1% DMSO in the medium).
MATERIALS AND METHODS

Chemicals
MDA-kb2 and GH3.TRE-Luc Cell Lines
Resazurin and TR reporter gene assay using the GH3.TRE-Luc cell line. The GH3.TRE-Luc cell line, described by Freitas et al. (2011) , (gift from the Wageningen University, Toxicology Department, The Netherlands) was maintained in Dulbecco's Modified Eagle's medium: Ham's F12 (1:1) with 15 mM HEPES (DMEM/F12, Gibco) supplemented with 10% fetal bovine serum (Gibco), 100 U/ml penicillin (Sigma), 100 mg/ml streptomycin (Sigma) at 37 C in an atmosphere containing 5% CO 2 . GH3.TRE-Luc cells were seeded at 80% confluency in 75 cm 2 culture flasks (TPP, Techno Plastic
Products AG, Switzerland) in growth medium. After 24 h, the growth medium was replaced by serum free medium PCM for the next 24 h. For experiments, cells were seeded into 96-well plates at a density of 3 Â 10 4 cells/well and incubated for 24 h in the presence (0.25 nM) or absence of T 3 , with the test chemical in DMSO. The concentration of DMSO was always the same within an experiment and always kept at <0.5% (v/v) to avoid cytotoxicity. The metabolic activity of cells (GH3.TRE-Luc) was determined using the reduction of resazurin to the fluorescent resorufin as previously described (O'Brien et al., 2000; Schriks et al., 2006) . Following the 24 h exposure to the test chemical, 10 ml of a 400 mM resazurin (Gibco) solution was added to each well. Fluorescence was measured after 4 h of incubation in the dark (37 C; 5% CO 2 ; kex ¼ 530 nm and kem ¼ 590 nm) with the automatic microplate reader Synergy 4 Hybrid Microplate Reader (BioTek, Winooski, Vermont, USA). Luciferase activity was then measured on lysed cells as described ("AR and GR reporter gene assays using MDA-kb2 cell line" section).
PolarScreen GR Competitor Assay
PolarScreen GR Competitor Assay Kit, Green (Invitrogen) is used to determine the relative affinity of tested compounds for the GR (www.lifetechnologies.com/order/catalog/product/A15897). After 2 h incubation at room temperature, fluorescence polarization was measured with kex ¼ 485 nm and kem ¼ 535 nm, bandwidths of 25/20 nm with the automatic microplate reader Synergy 4 Hybrid Microplate Reader (BioTek, Winooski, Vermont, USA).
PolarScreen AR Competitor Assay
PolarScreen AR Competitor Assay Kit, Green (Invitrogen) is used to determine the relative affinity of tested compounds for the AR-LBD (www.lifetechnologies.com/order/catalog/product/ A15897). The same procedure was used as in the GR competitor assay ("PolarScreen AR Competitor Assay" section).
Data and Statistical Analysis
The data shown are means 6 SD of at least 3 independent experiments with duplicate or triplicate wells for each experiment. The coefficient of variation is the result of replicates in the experimental design. Data were analyzed by 1-way analysis of variance, followed by Student-Newman-Keuls post hoc test, where *P < .05, **P < .01, and ***P < .001 were considered statistically significant. The median effective concentration (EC 50 ) and median inhibitory concentration (IC 50 ) were fitted using the sigmoid dose-response function in GraphPad Prism 5.01 software for Windows (GraphPad Software Inc., San Diego, Californina, USA, www.graphpad.com). 
RESULTS
Cytotoxicity of Tested Compounds and Their Mixtures
The maximum non-toxic concentration of each compound and of their mixtures used for detection of (anti)glucocorticoid-, (anti)androgen-, and (anti)thyroid hormone-like activity was determined as previously described by MTS and resazurin assay. Concentrations with metabolic activity over 0.8-fold were considered not to be cytotoxic. 2MR and BHA showed no cytotoxicity at 175 M and 50 lM concentrations in glucocorticoid-, anti-androgen-, and anti-glucocorticoid-like assays (Figs. 2A, B , and D). AVB showed no cytotoxicity at 1 lM concentration in glucocorticoid-and anti-androgen-like assays ( Figs. 2A and B) . Poor solubility was the reason for selecting the lower concentrations of tested compounds in thyroid hormone-like and antithyroid hormone-like assays (Figs. 2C and E) . The only exception is AVB witch causes no cytotoxicity at 25 lM concentration in the anti-thyroid hormone-like assay (Fig. 2E) . Mixtures showed no cytotoxicity at the concentrations tested (EC 50 or IC 50 ) (Figs. 2F-H).
Glucocorticoid-like Activities
In order to distinguish between the GR and AR, cells were cotreated with androgen antagonist FLUT (5 lM) for 30 min ( Figure. 3A). The known glucocorticoid agonist, HC, showed the appropriate luciferase response in the MDA-kb2 cell line with an EC 50 value of 0.1 lM. Maximum induction of 7.81-fold of vehicle control was achieved at a concentration of 10 lM. All 3 compounds tested (2MR, BHA, and AVB) demonstrated glucocorticoid-like activities by inducing the expression of luciferase with EC 50 values of 1.24 lM, 0.1 nM, and 2.7 fM, respectively. The maximum values of induction of 2MR, BHA and AVB were smaller than those for the HC control (Table 2) which was reached at concentrations of 0.01, 0.5, and 1 lM. Based on their EC 50 values the order of the glucocorticoid-like activities of these compounds was in the 2MR < BHA < AVB.
Anti-Androgen-like Activities
When the known androgen antagonist FLUT was co-treated with androgen agonist DHT (0.5 nM) for 30 min, luciferase expression was suppressed significantly ( Figure 3B ). The IC 50 value was 4.57 lM with 0.65-fold of vehicle control reached at concentration of 10 lM. From the dose-response curves for 2MR, BHA, and AVB, their IC 50 values were 83.02 lM, 4 nM, and 17 pM.
Values of maximum induction of the luciferase response (nfold) for the compounds are comparable with the value of the positive control (FLUT), but were reached at different concentrations ( Table 2 ). The strongest anti-androgen-like activity for single compounds was observed for AVB, then compound BHA, and then for the weakest compound, 2MR.
Thyroid Hormone-like Activities The GH3.TRE-Luc reporter system is an appropriate system for assaying thyroid hormone-like activity. The natural TR ligand, T 3, induced luciferase activity in a concentration-dependent manner with an EC 50 of 0.16 lM. The maximum induction of 13.28-fold of vehicle control was achieved at 100 lM concentration. Tested compounds (2MR, BHA, and AVB) were shown to possess thyroid hormone-like activities, with EC 50 values of 0.03 lM, 0.1 nM, and 1 nM, respectively. Details are listed in Table 2 .
Anti-Glucocorticoid-like Activity
To measure anti-glucocorticoid-like activity, cells were cotreated with the glucocorticoid agonist HC (500 nM) for 30 min and its suppression of the maximum luciferase expression observed ( Figure 3D ). A maximum inhibition for AVB of 0.19-fold of vehicle control was achieved at 25 lM concentration. All 3 tested compounds showed anti-thyroid hormone-like activity, with different potencies in the order 2MR < BHA < AVB.
The Binding of Tested Compounds to the GR
Competition for binding to the GR was displayed by compound AVB with an IC 50 of 2.52 nM (Figure 4 ). HC was used as positive control, (IC 50 of 9.34 nM).
Binding Potential of the Tested Compounds to the AR
The androgen and anti-androgen-like activities of tested compounds, determined in the luciferase assay, were the basis for investigating their binding potential to the AR ( Figure 5 ). Competition for binding to the AR was displayed by compounds 2MR and AVB, with IC 50 values of 0.19 nM and 1.2 mM. DHT was used as positive control (IC 50 was 19.47 nM).
Glucocorticoid-like, anti-Androgen-like and Thyroid Hormone-like Activities of Mixtures
Based on previous results for the dose-response of compounds alone, only glucocorticoid-like, anti-androgen-like and thyroid hormone-like activities of mixtures were determined, using a luciferase gene assay. All possible combinations of 3 compounds were tested in binary and ternary component mixtures, together with the compounds alone, at their EC 50 or IC 50 concentrations ( Figure 6 ). Compounds alone exhibited no glucocorticoid-, anti-androgen-, or thyroid hormone-like activities, with the exception of AVB with a glucocorticoid-like activity of 1.2-fold over vehicle control ( Figure 6A ). The binary combinations, 2MR þ BHA and 2MR þ AVB, showed glucocorticoid-and antiandrogen-like activities. Induction of luciferase response over vehicle control was 1.13-fold for glucocorticoid-like activity and 0.81-fold for anti-androgen-like activity. A ternary combination 2MR þ BHA þ AVB, exhibited only a glucocorticoid-like activity, 1.2 times higher than vehicle control. co-treated with the thyroid hormone agonist T3 (E) for 24 h. Afterwards MTS (A, B, D, F, and G) and resazurin (C, E and H) were added and absorbance and fluorescence were measured after 4 h. Each column is the mean 6 SD of at least 3 independent experiments. *P < .05, **P < .01, and ***P < .001 were considered statistically significant compared with the respective 0.1% DMSO control. 
DISCUSSION
In this study, the anti-androgen-, glucocorticoid-, and thyroid hormone-like activities of 3 widely used cosmetic ingredients (2MR, BHA, and AVB) and their mixtures, were determined and compared at their EC 50 or IC 50 concentrations. Furthermore, the compounds were also shown to possess anti-glucocorticoid-like and anti-thyroid hormone-like activities. Two cell lines were chosen-the MDA-kb2 and GH3.TRE-Luc reporter cell lines, both appropriate for determining endocrine disruption compounds (Chinta et al., 2015; Freitas et al., 2011; Klop ci c et al., 2016; Nishizaki et al., 2009; Skledar et al., 2016; Wilson et al., 2002) . Our evaluations are based on dose response data for single compounds and on the luciferase response over control for mixtures at EC 50 or IC 50 concentrations. The results support the concerns for human health posed by probable endocrine disruption compounds.
2MR, BHA and AVB Influence on TR, AR, and GR
The results obtained provide new information about the tested compounds 2MR, BHA, and AVB exhibit anti-androgen-, glucocorticoid-like and, with the exception of AVB, antiglucocorticoid-like activities in in vitro AR and GR reporter gene assays using the MDA-kb2 cell line. Furthermore, these results are the first to show anti-thyroid hormone-like and thyroid hormone-like activities, using the new GH3.TRE-Luc reporter cell line (Freitas et al., 2011) . The AVB compound was the most active of the compounds tested in AR antagonist, GR agonist, and TR antagonist reporter gene assays (Table 2) . In all tests, based on values of EC 50 or IC 50 the activities of the tested compounds were in the same order 2MR < BHA < AVB, the exception being thyroid hormone-like activity. The BHA compound showed stronger anti-glucocorticoid-like activity than 2MR. In addition, the 2MR compound exhibited the lowest activity on all 3 tested receptors. Further only AVB modulates the ligand binding of the GR. In this study, as well as AVB, 2MR has been found to be a mimetic of androgen action with direct binding to receptor. Interesting to note, according to the IC 50 , the potency of the AVB and BHA for the AR were higher compared with the known AR antagonist FLUT (Table 2) . Furthermore, maximum induction of luciferase response over vehicle control was 0.19-fold for AVB, which indicates the stronger antagonistic activity compared with the maximum induction of luciferase response over vehicle control for known anti-thyroid hormone compound BPA (0.3-fold).
2MR is classified as an environmental agent that produces an anti-thyroid effect (Rom an, 2007) , the latter being supported by our results. However, we have also, for the first time, observed thyroid hormone-like activity. In vitro studies have reported that BHA possesses agonistic activity on the ER (Jobling and Sumpter, 1993; Pop et al., 2013; Soto et al., 1995) , together with anti-androgenic properties (a partial androgen antagonist [Schrader and Cooke, 2000] ), while, in an in vivo study, it was FIG. 6 . Luciferase response of the tested compounds alone and in mixtures. EC 50 or IC 50 concentrations of compound alone were chosen for cells treated with compound or mixture. The MDA-kb2 cells were pre-treated with (A) FLUT an androgen antagonist, (5 lM), (B) DHT, an androgen agonist, (0.5 nM) for 30 min. The GH3.TRELuc cells (C) without co-treatment with T3 (0.25 nM). The tested compound or mixture and the positive control (A) HC, 100 nM, (B) FLUT, 5 lM, (C) T3, 0.25 nM were then added and, after 24 h, luciferase activity was measured. Results are shown as means 6 SD of at least 3 independently performed assays; asterisks denote statistical significance compared with the respective 0.1% DMSO control: *P < .05, **P < .01, ***P < .001.
found to have anti-estrogenic properties (Pop et al., 2013) . Our results also demonstrate anti-androgen-like activity for BHA. In vitro and in vivo results for AVB indicate that it is a partial agonist on the ER, with direct binding to the ERb (Schlumpf et al., 2001; Schreurs et al., 2002; . Ma et al. (2003) also used the MDA-kb2 cell line to test the possible agonistic or antagonistic androgenic action of AVB, but no action was found. This apparent difference could be the result of using a different concentration of the agonist with which the test compound is competing (0.1 nM of DHT in their study). Furthermore, in another study (Schreurs et al., 2005) , a weak antagonistic effect toward the AR was shown, in agreement with our results. Such results appear to depend considerably on the species and cell type used, and on the different concentration range and different criteria used for positive agonist/antagonist test results.
Mixture Effects of the Compounds
In an attempt to simulate more common situations, we analyzed glucocorticoid-, anti-androgen-, and thyroid hormone-like activities of 1 binary and 1 ternary mixture at their EC 50 or IC 50 concentrations. Activities of mixtures of these compounds on the AR, GR, and TR for 2MR, BHA, and AVB are shown here for the first time. However, each of these compounds alone exhibits a different intensity of modulation of the AR, GR, and TR. Dose response curves show that each of the 3 compounds has glucocorticoid-, anti-androgen-, and (anti)-thyroid hormone-like activity in the 2 reporter cell lines.
As has been stressed earlier, all 3 compounds can be endocrine disruptors of 3 or more hormonal receptors, which should be considered in further in vivo testing. They are clearly a threat for human health and should not be omitted in risk assessment. That is why it is of interest to test their mixtures to see whether they interact with each other in synergistic or in other ways.
The similar exposure of humans in Europe and the United States to widely used compounds was basis for our selection. For the same reason we have demonstrated the glucocorticoid-, anti-androgen-, and thyroid hormone-like activities of mixtures (Figs. 6A-C) to estimate real exposures. Although only small glucocorticoid-and anti-androgen-like activities were observed, they are in agreement with the small or un-observable glucocorticoid-and anti-androgen-like activities of compounds alone in in vitro studies (Figs. 6A and B) . We conclude that mixture effects should be included in risk assessment of individual hormone disruptors.
We have shown that the binary mixtures of 2MR, BHA, and AVB exhibit glucocorticoid-and anti-androgen-like activities (Figs. 6A and B) . The ternary mixture showed a higher glucocorticoid-like activity than 2MR þ BHA, but one that is similar to those exerted by compound AVB and the known GR agonist HC at 100 nM ( Figure 6A) . Neither of the mixtures showed significant thyroid hormone-like activity ( Figure 6C ).
It is interesting to note that the AVB, that showed direct binding to the GR (based on its IC 50 value), showed no significant luciferase response over control when in combination with all other compounds in binary mixtures. Furthermore, ternary mixtures exhibited the same luciferase response as AVB alone. Once again, compounds 2MR and AVB, which showed direct binding to the AR, in different combinations, did not exert significant anti-androgen-like activity. The exception is the combination of 2MR and AVB, which displayed an anti-androgen-like activity similar to that exerted by the AR antagonist FLUT at 5 lM ( Figure 6B ). Binary and ternary mixtures displayed no thyroid hormone-like activities ( Figure 6C ). These results confirm existing concerns about the safety of mixtures and add an additional level of complexity to risk assessment.
The aim of this study was to test the potential endocrine disruption of the AR, GR, and TR by 3 daily used cosmetic ingredients 2MR, BHA, and AVB, and to establish the glucocorticoid-, anti-androgen-, and thyroid hormone-like activities of their different combinations at real human exposure levels. Although our results did not display any strong influence of mixtures on glucocorticoid-, anti-androgen-, and thyroid hormone-like activity compared with the ingredients alone, we conclude that they can also be responsible for endocrine disruption in humans in various combinations, which is probably the more common situation, because of their presence in different cosmetic preparations. Although some of the compounds alone exhibit binding to the AR (AVB and 2M) and GR (AVB), the effects of mixtures are probably the result of interaction of individual mixture constituents with different actions that may influence transactivation, binding, co-activation and expression of luciferase. Further analysis in in vivo systems is necessary.
In conclusion, this is one of the first studies to demonstrate the fact that the tested compounds AVB, 2MR, and BHA, in everyday use, possess anti-androgen-, (anti)-glucocorticoid-, and (anti)thyroid hormone-like activities. Furthermore, their different combinations also have the potential for endocrine disruption. Humans are exposed to more than 1 compound at the same time and such mixtures must therefore be present in humans. Our results show that tested compounds should not be dismissed as mimetics of normal endocrine system function. In our study, we have also shown that binary and ternary mixtures of tested compounds have glucocorticoid-like and antiandrogen-like activity but without thyroid hormone-like activity. Further we have concluded that combinations of compounds have different glucocorticoid-, anti-androgen-, and thyroid hormone-like activities as could be expected, and therefore that such mixture effects need to be included into risk assessment.
